吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标

老虎资讯综合2020-04-29

4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。

吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

斗彩鸡缸杯
2020-04-29
斗彩鸡缸杯
severe开放标签实验，5天10天未出现安全性风险变化，14天死亡率7％，已经算是很好的结论了
空间站
2020-04-29
空间站
重症啊！这个新闻写了severe.
- 青年诸葛亮:
  press release里面的标题就写的是重症啊。。。
- 斗彩鸡缸杯:
  severe怕不会是轻症吧
- v斯达克:
  仔细读，还是轻症。跟之前报告给的结论一样，没有差别
天恶方入眼
2020-04-29
天恶方入眼
还有**在吹这个药呢。哈哈哈，这个药真有疗效，欧美上层怎么不用啊？摆明了现在还在收割傻子菜。
泡泡糖888
2020-04-29
泡泡糖888
人民的希望，就等着一天了，加油，大家出来的时间快到了，期待！
小看风云
2020-04-29
小看风云
感觉含含糊糊的。看来神药出世病毒也被消灭的差不多了
金牛区亨利雷曼
2020-04-29
金牛区亨利雷曼
中西药利益集团一个德性，实验方案说改就改，祝愿灯塔五月复工愉快，我呸！

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1108976612?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","is_english":false,"pubTime":"2020-04-29 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108976612","market":"us","top_or_hot":-1,"title":"吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标","media":"老虎资讯综合","content":"<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标\n</h2>\n\n<h4 class=\"meta\">\n\n2020-04-29 20:37 北京时间&nbsp;&nbsp;&nbsp;<strong>老虎资讯综合</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":null,"article_id":"1108976612","we_media_id":"102","thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108976612","pubTimestamp":1588163821,"sourceInfo":null,"weMediaInfo":{"media_name":"老虎资讯综合","introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"The clinical trial of Redhivir's new crown in Gilead Sciences has reached the main evaluation indicators.","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/79c0f963d4ee2a972229cfdadeae82fc","symbols_score_info":{"GILD":0.9},"content_text":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":924080905,"gmtCreate":1588166662507,"gmtModify":1704366705707,"author":{"id":"3543609131664174","authorId":"3543609131664174","name":"斗彩鸡缸杯","avatar":"https://static.tigerbbs.com/4a09124ab57f96953e357b27d7692b1f","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"severe开放标签实验，5天10天未出现安全性风险变化，14天死亡率7％，已经算是很好的结论了","listText":"severe开放标签实验，5天10天未出现安全性风险变化，14天死亡率7％，已经算是很好的结论了","text":"severe开放标签实验，5天10天未出现安全性风险变化，14天死亡率7％，已经算是很好的结论了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/924080905","repostId":1108976612,"repostType":2,"repost":{"id":"1108976612","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1588163821,"share":"https://www.laohu8.com/m/news/1108976612?lang=&edition=full","pubTime":"2020-04-29 20:37","market":"us","language":"zh","title":"吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标","url":"https://stock-news.laohu8.com/highlight/detail?id=1108976612","media":"老虎资讯综合","summary":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治","content":"<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2020-04-29 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"GILD":"吉利德科学"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108976612","content_text":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":924011343,"gmtCreate":1588165810382,"gmtModify":1704366695593,"author":{"id":"3494204292286627","authorId":"3494204292286627","name":"空间站","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"重症啊！这个新闻写了severe.","listText":"重症啊！这个新闻写了severe.","text":"重症啊！这个新闻写了severe.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/924011343","repostId":1108976612,"repostType":2,"repost":{"id":"1108976612","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1588163821,"share":"https://www.laohu8.com/m/news/1108976612?lang=&edition=full","pubTime":"2020-04-29 20:37","market":"us","language":"zh","title":"吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标","url":"https://stock-news.laohu8.com/highlight/detail?id=1108976612","media":"老虎资讯综合","summary":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治","content":"<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2020-04-29 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"GILD":"吉利德科学"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108976612","content_text":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":2392915,"gmtCreate":1588166860381,"gmtModify":1588166860381,"authorId":3540464560321511,"author":{"id":3540464560321511,"authorId":3540464560321511,"name":"青年诸葛亮","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":924011343,"type":1,"supId":2392840,"prevId":0,"content":"press release里面的标题就写的是重症啊。。。","text":"press release里面的标题就写的是重症啊。。。","html":"press release里面的标题就写的是重症啊。。。"},{"id":2392881,"gmtCreate":1588166545504,"gmtModify":1588166545504,"authorId":3543609131664174,"author":{"id":3543609131664174,"authorId":3543609131664174,"name":"斗彩鸡缸杯","avatar":"https://static.tigerbbs.com/4a09124ab57f96953e357b27d7692b1f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":924011343,"type":1,"supId":2392840,"prevId":0,"content":"severe怕不会是轻症吧","text":"severe怕不会是轻症吧","html":"severe怕不会是轻症吧"},{"id":2392840,"gmtCreate":1588166269776,"gmtModify":1588166269776,"authorId":3459951462000451,"author":{"id":3459951462000451,"authorId":3459951462000451,"name":"v斯达克","avatar":"https://static.tigerbbs.com/203336786a87ea66e6a2cb95b13a6c4d","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":924011343,"type":1,"supId":0,"prevId":0,"content":"仔细读，还是轻症。跟之前报告给的结论一样，没有差别","text":"仔细读，还是轻症。跟之前报告给的结论一样，没有差别","html":"仔细读，还是轻症。跟之前报告给的结论一样，没有差别"}],"langContent":"CN"},{"id":924013063,"gmtCreate":1588165726052,"gmtModify":1704366693495,"author":{"id":"3514962389798776","authorId":"3514962389798776","name":"天恶方入眼","avatar":"https://static.tigerbbs.com/ed8f9d3d9faf31c0a457cdf0299e29ff","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"还有**在吹这个药呢。哈哈哈，这个药真有疗效，欧美上层怎么不用啊？摆明了现在还在收割傻子菜。","listText":"还有**在吹这个药呢。哈哈哈，这个药真有疗效，欧美上层怎么不用啊？摆明了现在还在收割傻子菜。","text":"还有**在吹这个药呢。哈哈哈，这个药真有疗效，欧美上层怎么不用啊？摆明了现在还在收割傻子菜。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/924013063","repostId":1108976612,"repostType":4,"repost":{"id":"1108976612","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1588163821,"share":"https://www.laohu8.com/m/news/1108976612?lang=&edition=full","pubTime":"2020-04-29 20:37","market":"us","language":"zh","title":"吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标","url":"https://stock-news.laohu8.com/highlight/detail?id=1108976612","media":"老虎资讯综合","summary":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治","content":"<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2020-04-29 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"GILD":"吉利德科学"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108976612","content_text":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":924019609,"gmtCreate":1588165620201,"gmtModify":1704366692743,"author":{"id":"3473047601612989","authorId":"3473047601612989","name":"泡泡糖888","avatar":"https://static.tigerbbs.com/5aaebfbfd9f8d00bdd8575be63bb27a8","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"人民的希望，就等着一天了，加油，大家出来的时间快到了，期待！","listText":"人民的希望，就等着一天了，加油，大家出来的时间快到了，期待！","text":"人民的希望，就等着一天了，加油，大家出来的时间快到了，期待！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/924019609","repostId":1108976612,"repostType":2,"repost":{"id":"1108976612","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1588163821,"share":"https://www.laohu8.com/m/news/1108976612?lang=&edition=full","pubTime":"2020-04-29 20:37","market":"us","language":"zh","title":"吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标","url":"https://stock-news.laohu8.com/highlight/detail?id=1108976612","media":"老虎资讯综合","summary":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治","content":"<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2020-04-29 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"GILD":"吉利德科学"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108976612","content_text":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":924010988,"gmtCreate":1588165426544,"gmtModify":1704366691158,"author":{"id":"3548657458760362","authorId":"3548657458760362","name":"小看风云","avatar":"https://static.tigerbbs.com/d70109a8ba72ce1f430c6b3785a32bf8","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"感觉含含糊糊的。看来神药出世病毒也被消灭的差不多了","listText":"感觉含含糊糊的。看来神药出世病毒也被消灭的差不多了","text":"感觉含含糊糊的。看来神药出世病毒也被消灭的差不多了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/924010988","repostId":1108976612,"repostType":2,"repost":{"id":"1108976612","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1588163821,"share":"https://www.laohu8.com/m/news/1108976612?lang=&edition=full","pubTime":"2020-04-29 20:37","market":"us","language":"zh","title":"吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标","url":"https://stock-news.laohu8.com/highlight/detail?id=1108976612","media":"老虎资讯综合","summary":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治","content":"<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2020-04-29 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"GILD":"吉利德科学"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108976612","content_text":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":924034797,"gmtCreate":1588165324119,"gmtModify":1704366688885,"author":{"id":"3495425425059761","authorId":"3495425425059761","name":"金牛区亨利雷曼","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"中西药利益集团一个德性，实验方案说改就改，祝愿灯塔五月复工愉快，我呸！","listText":"中西药利益集团一个德性，实验方案说改就改，祝愿灯塔五月复工愉快，我呸！","text":"中西药利益集团一个德性，实验方案说改就改，祝愿灯塔五月复工愉快，我呸！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/924034797","repostId":1108976612,"repostType":2,"repost":{"id":"1108976612","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1588163821,"share":"https://www.laohu8.com/m/news/1108976612?lang=&edition=full","pubTime":"2020-04-29 20:37","market":"us","language":"zh","title":"吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标","url":"https://stock-news.laohu8.com/highlight/detail?id=1108976612","media":"老虎资讯综合","summary":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治","content":"<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2020-04-29 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"GILD":"吉利德科学"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108976612","content_text":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":18,"commentSize":19,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108976612"}